Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Burkitt Lymphoma 9Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma, Large B-Cell, Diffuse 2Prostatic Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Plasmablastic Lymphoma 1Multiple Myeloma 1Lymphoma, T-Cell 1Lymphoma, Follicular 1Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 1Leukemia, Biphenotypic, Acute 1Down Syndrome 1

Interventions

Etoposide 3daratumumab 2Vincristine 2Prednisone 2Doxorubicin 2Cyclophosphamide 2prednylidene 1pomalidomide 1deltacortene 1carmustine, poliferprosan 20 drug combination 1Rituximab 1Peripheral Blood Stem Cell Transplantation 1Melphalan 1Dexamethasone 1Cytarabine 1Carmustine 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Plasmablastic Lymphoma × deltacortene × 30 days × Clear all
NCT04139304 2026-06-01

A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma

AIDS Malignancy Consortium

Phase EARLY_PHASE1 Recruiting
15 enrolled
Lymphoid

Plasmablastic Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡